Antipsychotic use in children twelve and under – do the benefits outweigh the risks? A review of the literature

Abstract

Antipsychotic medications are widely used in adult psychiatry, yet their use in children, particularly those aged twelve and under, raises serious clinical and ethical concerns. While some antipsychotics are approved for specific pediatric conditions such as early-onset schizophrenia, the majority of prescriptions in this age group are for off-label uses to target behavioral symptoms such as irritability, aggression, and hyperactivity. Evidence regarding safety, efficacy, long-term outcomes, and optimal dosing in young children remains limited. This literature review examines recent research on prescribing trends, efficacy, safety, monitoring practices, and potential benefits of antipsychotic use in children aged twelve and under. Findings highlight high rates of off-label prescribing, limited evidence for behavioral symptom management, and significant risk of metabolic, neurological, and cardiovascular adverse effects. Inadequate guideline-based monitoring, poor follow-up, and insufficient patient and family education further compound the potential for harm. Despite these concerns, short-term, closely-monitored use has been shown to provide benefit in exceptional cases. The review concludes that antipsychotic prescribing in young children should prioritize non-pharmacologic interventions, with medications being reserved for situations where the potential benefits clearly outweigh the substantial risks, and emphasizes the need for improved monitoring, education, and age-specific research to support safer, evidence-informed practice.